ORIC
Oric Pharmaceuticals, Inc.
$10.85
-0.09 (-0.82%)
At close · Jul 10
Market Cap
$1.12B
Shares
103,517,562
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.85
Open$11.04
Day$10.38–11.17
52W$7.23–14.93
Avg vol 30d2.0M
Short int22.1M · 21.4% float · 12.3d
Short vol59%
Last earningsMar 21, 2022
DataApr 2020–Jul 2026
Filing10-Q · May 4
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 4, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
+20%
above
RSI (14)
65
neutral
MACD trend
Positive
52-week position
47%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+44%
trailing
6-month return
−6%
trailing
YTD return
+33%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $11 — 200d above 50d
Institutional flow
Distributing
4 of 181 funds reported for Jun 30 · net -160.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.36% of float · ▲ +5.0% MoM · 12.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
181 holders — near 3-yr high, broad support
Squeeze score
86
high risk · 0–100
Fundamentals
EPS growth
+20%
Y/Y
Free cash flow
$-111.7M
Balance sheet
$35.2M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
+20%
Bullish
RSI (14)
65
Neutral
MACD trend
Positive
Bullish
52-week position
47%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $11 — 200d above 50d
Institutional flow
Distributing
4 of 181 funds reported for Jun 30 · net -160.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.36% of float · ▲ +5.0% MoM · 12.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
181 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $7
Now $11 · 47%
52-wk high $15
vs 200-day avg +2%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ORIC
this stock
Oric Pharmaceuticals, Inc.
|
$1.12B | +32.6% | — | — | 21.4% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ORIC | -6.8% | +43.9% | -5.8% | +0.2% | +32.6% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -8.2% | +39.8% | -14.9% | -0.9% | +21.9% |